Recent treatment of dry eye

Young Joo Shin

doi:10.5124/jkma.2019.62.4.218

J Korean Med Assoc > Volume 62(4); 2019 > Article

Shin: Recent treatment of dry eye

Pharmacotherapeutics

Journal of the Korean Medical Association 2019; 62(4): 218-223.

Published online: April 11, 2019

DOI: http://dx.doi.org/10.5124/jkma.2019.62.4.218

Recent treatment of dry eye

Young Joo Shin, MD

Department of Ophthalmology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.

Corresponding author: Young Joo Shin. schinn@hanmail.net

Received March 22, 2019 Accepted March 29, 2019

Korean Medical Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Dry eye disease is a disease characterized by ocular irritation symptoms, tear film instability and ocular surface inflammation. Dry eye is due to aqueous tear deficiency or excessive tear evaporation, which causes damage to the ocular surface and is associated with ocular discomforts. A lot of therapy has been developed for treatment and management of dry eye disease. In this article, we review the current therapy for dry eye disease. We present the characteristics and efficacy of therapy for dry eye disease. We believe that our review will aid clinicians in the treatment of patients with dry eye disease.

Dry eye disease; Tear film; Therapy

References

1. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II definition and classification report. Ocul Surf 2017;15:276-283.

2. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, Uchino Y, Yokoi N, Zoukhri D, Sullivan DA. TFOS DEWS II pathophysiology report. Ocul Surf 2017;15:438-510.

3. Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Benítez-del-Castillo J, Boboridis KG, Merayo-Lloves J, Rolando M, Labetoulle M. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol 2016;100:300-306.

4. Chhadva P, Goldhardt R, Galor A. Meibomian gland disease: the role of gland dysfunction in dry eye disease. Ophthalmology 2017;124:S20-S26.

5. Borchman D. The optimum temperature for the heat therapy for meibomian gland dysfunction. Ocul Surf 2019;02. 19. [Epub]. 10.1016/j.jtos.2019.02.005.

6. Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y, Seo KY, Tauber J, Wakamatsu TH, Xu J, Wolffsohn JS, Craig JP. TFOS DEWS II management and therapy report. Ocul Surf 2017;15:575-628.

7. Drug and Therapeutics Bulletin. The management of dry eye. BMJ 2016;353:i2333.

8. Pescosolido N, Parisi F, Buomprisco G, Librando A. New therapies in common ocular surface disorders. Clin Ter 2013;164:e405-e411.

9. Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev 2017;2:CD009327.

10. Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2010;(9):CD006775.

11. Nam K, Kim HJ, Yoo A. Efficacy and safety of topical 3% diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials. Ophthalmic Res 2019;01. 17. [Epub]. 10.1159/000492896.

12. Holland EJ, Darvish M, Nichol KK, Jones L, Karpecki PM. Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: a systematic literature review. Ocul Surf 2019;03. 04. [Epub]. 10.1016/j.jtos.2019.02.012.

13. Keating GM. Diquafosol ophthalmic solution 3 %: a review of its use in dry eye. Drugs 2015;75:911-922.

14. Zhao X, Xia S, Chen Y. Comparison of the efficacy between topical diquafosol and artificial tears in the treatment of dry eye following cataract surgery: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017;96:e8174.

15. Burnstock G. The therapeutic potential of purinergic signalling. Biochem Pharmacol 2018;151:157-165.

16. Igarashi T, Fujita M, Yamada Y, Kobayashi M, Fujimoto C, Takahashi H, Igarashi T, Nakano Y, Suzuki H, Takahashi H. Improvements in signs and symptoms of dry eye after instillation of 2% rebamipide. J Nippon Med Sch 2015;82:229-236.

17. Lee H, Kim M, Park SY, Kim EK, Seo KY, Kim TI. Mechanical meibomian gland squeezing combined with eyelid scrubs and warm compresses for the treatment of meibomian gland dysfunction. Clin Exp Optom 2017;100:598-602.

18. Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol 2013;7:1797-1803.

19. Thode AR, Latkany RA. Current and emerging therapeutic strategies for the treatment of meibomian gland dysfunction (MGD). Drugs 2015;75:1177-1185.

20. Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea 2013;32:44-53.

21. Dogru M, Nakamura M, Shimazaki J, Tsubota K. Changing trends in the treatment of dry-eye disease. Expert Opin Investig Drugs 2013;22:1581-1601.

22. Keating GM. Lifitegrast ophthalmic solution 5%: a review in dry eye disease. Drugs 2017;77:201-208.

23. Albietz JM, Schmid KL. Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction. Clin Exp Optom 2018;101:23-33.

24. Vora GK, Gupta PK. Intense pulsed light therapy for the treatment of evaporative dry eye disease. Curr Opin Ophthalmol 2015;26:314-318.